Vivimed Labs has proposed to acquire Finoso Pharma for a total consideration of Rs 15 crore comprising cash, stock and deferred payment. Post acquisition, Finoso will become Vivimed’s research and development (R&D) unit to support innovators, generics and licensing efforts.
Finoso Pharma is a pharmaceutical development services company focused on formulations product development efforts for multiple markets and develops globally accepted dossiers.